Evaluation of Inflammatory Markers in ph Negative Myeloproliferative Neoplasms: Impact on Outcome and Response to Therapy. Multicenter Retro-prospective Observational Study. The INFLA-ME (INFLAmmation in Myeloproliferative Disease) Study.
NCT ID: NCT05553873
Last Updated: 2024-01-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
500 participants
OBSERVATIONAL
2022-09-08
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement
NCT00573326
Evaluation of the Serum Soluble Fractalkine as a Biomarker of Pulmonary Fibrosis in Systemic Sclerosis
NCT03508375
Phenotypic and Functional Profile of Peripheral Blood Lymphomonocytes in Seborrheic Dermatitis.
NCT07297446
Identification of Oral Lesions Through an Autofluorescence System
NCT05942794
Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases
NCT06599411
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of PV, ET, PMF or post PV and post ET MF, according to current WHO or IWG-MRT criteria (diagnosis since 2000)
* Obtaining informed consent
Exclusion Criteria
* Accelerated phase myelofibrosis or MPN with signs of leukemic evolution
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Milano Bicocca
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Azienda Ospedaliera Universitaria Consorziale Policlinico
Bari, , Italy
Policlinico Sant'Orsola Malpighi
Bologna, , Italy
ASST Spedali Civili di Brescia
Brescia, , Italy
Policlinico Vittorio Emanuele
Catania, , Italy
Ospedale Universitario Federico II
Napoli, , Italy
Policlinico Umberto I, Università La Sapienza
Roma, , Italy
Azienda Ospedaliera Universitaria Città della Salute e delle Scienza
Torino, , Italy
Ospedale San Luigi di Orbassano - Ospedale Mauriziano
Torino, , Italy
Azienda Ospedaliera Universitaria Friuli Centrale
Udine, , Italy
Azienda Ospedaliera Universitaria Integrata
Verona, , Italy
Ospedale Belcolle
Viterbo, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Massimo Breccia
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
INFLA-ME
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.